Lung Biology Center


Dartmouth's Lung Biology Center is a premier hub for high-impact research that yields life-changing results. Its contributions to the understanding and treatment of cystic fibrosis and other lung diseases include the discovery of new drugs, breakthroughs in the battle against infections, and the transformation of care of patients with cystic fibrosis across the country.

Your support for the Lung Biology Center will provide the sustaining and flexible funding needed to fuel such discoveries and translate them rapidly into patient care and disease prevention.

Read more about the Lung Biology Center

Lung Biology Center researchers are . . .

  • Finding ways to combat antibiotic resistance
  • Testing novel methods of medicine delivery
  • Developing better diagnostics to more rapidly and precisely treat dangerous infections
  • Using stem cell injections to repair damaged lungs
  • Creating mathematical and computational disease models to accelerate discovery and personalize patient care

Almost all of us experience bacterial or viral respiratory infections in any given year. For most of us, the illness is temporary, but for millions the effects are far more severe. Lower respiratory infections from bacteria, fungi, and viruses are the third leading cause of death in the U.S. Millions of Americans live with often disabling lung conditions, such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, and cystic fibrosis—which is the most common lethal genetic disease in the U.S. and still prevents many children from reaching adulthood.

Overcoming these chronic and deadly lung diseases is the focus of over 200 scientists, physicians, and trainees at Dartmouth’s Geisel School of Medicine and Dartmouth-Hitchcock Health—who collaborate through Dartmouth’s Lung Biology Center.

Its scientific success and impact lies in its multidisciplinary approach: microbiologists, biochemists, immunologists, neonatologists, pulmonologists, computational biologists, engineers, and data scientists working together to make advances that are both fundamental and cutting edge.

1 of 7 Cystic Fibrosis Research and Translation Centers funded by the National Institutes of Health
1 of 11 Research Development Programs funded by the Cystic Fibrosis Foundation

Learn about gift opportunities

Campaign Goal: $10 million

Your support can accelerate the pace of discovery and the translation of those discoveries into personalized, highly effective therapies for patients with chronic lung diseases. The Lung Biology Center has identified the following philanthropic goals and giving opportunities.

Catalyze the growth of high-potential, groundbreaking research. An infusion of current-use gifts and an endowed innovation fund will provide the resources needed to grow new high-potential lines of research. (Goal: $3.5 million)

  • Endowed Innovation Fund ($100,000 - $1.5 million)
  • Microbiome of Lung Disease Research ($10,000 - $1 million)
  • Stem Cell and Lung Disease Research ($10,000 - $1 million)

Attract and retain the most innovative faculty. Endowed support provides faculty with the time and freedom to conduct more high-risk–high-reward research that departs from the “safe bets” typically supported by traditional and short-term extramural sources. (Goal: $6 million)

  • Named Professorships ($4 million each)
  • Named Faculty Fellowships ($1 million each)

Enhance learning opportunities for Dartmouth students. Serving as teacher-scholars, Lung Biology faculty welcome dozens of graduate and undergraduate students into their labs as research partners, helping to prepare them for roles as future leaders in science and medicine. Faculty often remark on the energy, creativity, and commitment that Dartmouth students bring to their teams. (Goal: $500,000)

  • Named Student Research Opportunities ($100,000 each)

At Dartmouth’s Lung Biology Center, every $1 in pilot funding has led to $60 in external grant funding.


Brody Fund Sustains Momentum in Pulmonary Fibrosis Research

Could there be a connection between chronic inflammatory lung diseases, such as pulmonary fibrosis, and chronic autoimmune diseases, such as rheumatoid arthritis? That’s one of the important questions that Dr. Richard Enelow, a professor of medicine and of microbiology and immunology at the Geisel School of Medicine and a pulmonologist at Dartmouth-Hitchcock, is exploring in his research laboratory.

Read More


For more information, please contact Tricia Butterfield:
Patricia.C.Butterfield@hitchcock.org  |  603-653-0755